drugset / Trial / NCT00144963

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00144963

Phase 1/2 Completed 36 enrolled Acrotech Biopharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Timeline

Start
2002-07
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vincristine Small molecule Intravenous
Background Dexamethasone Small molecule 40 mg Oral